详情页 - 云南省第一人民医院机构库

当前位置：首页 > 详情页

A novel study on the immunomodulatory effect of umbilical cord derived mesenchymal stem cells pretreated with traditional Chinese medicine Asarinin.

191| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Hematology, The First People’s Hospital of Yunnan Province, Kunming, China [2]Yunnan Blood Disease Clinical Medical Center, Kunming, China [3]Yunnan Blood Disease Hospital, Kunming, China d Kunming University of Science and Technology, Kunming, China

出处：

DOI：

ISSN：

摘要：

Allogeneic hematopoietic stem cell transplantation (HSCT) remains the key for the treatment of malignant hematological diseases, and acute graft-versus-host disease (aGVHD) that might occur after allogenic transplantation can be life threatening and promote disease recurrence. GVHD damages the various parts of the body by upregulating T helper 1 cytokines (Th1) cytokines and stimulating CD4、CD8 + T cells. GVHD can exhibit significant immunoregulatory effects, but could be easily affected by the mesenchymal stem cells (MSC) environment, and hence the MSC immunosuppressive effects on GVHD remain unpredictable. Hence, to better understand the role of MSC in the prevention and treatment of GVHD, umbilical cord derived mesenchymal stem cells (UC-MSC) were pre-treated with Chinese medicine Asarinin and IFN-γ. In the mix lymphocyte reaction, we found that Asarinin pre-treated UC-MSC can exert significantly greater inhibition towards the proliferation of CD4 and CD8 + T cells, down-regulate Th1 type cytokines, up-regulate Th2 type cytokines, and reduce the inflammatory damage to liver, lung and intestine of aGVHD mice model. Moreover, Asarinin can cooperate with IFN-γto promote UC-MSC to secrete indoleamine 2,3-dioxygenase (IDO). Our findings establish that Asarinin pre-treated UC-MSC can significantly promote the immunosuppressive effects of MSC on aGVHD after hematopoietic stem cell transplantation.Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 2 区医学

小类 | 2 区药学 3 区免疫学

最新[2023]版：

大类 | 2 区

医学

小类 | 2 区免疫学 2 区药学

JCR分区：

出版当年[2020]版：

Q2 IMMUNOLOGY Q2 PHARMACOLOGY & PHARMACY

最新[2023]版：

Q1 PHARMACOLOGY & PHARMACY Q2 IMMUNOLOGY

影响因子： 4.8 最新[2023版] 5 最新五年平均 4.932 出版当年[2020版] 4.624 出版当年五年平均 3.943 出版前一年[2019版] 5.714 出版后一年[2021版]

第一作者：

第一作者机构： [1]Department of Hematology, The First People’s Hospital of Yunnan Province, Kunming, China [2]Yunnan Blood Disease Clinical Medical Center, Kunming, China [3]Yunnan Blood Disease Hospital, Kunming, China d Kunming University of Science and Technology, Kunming, China [*1]Yunnan blood disease clinical medical center, Yunnan blood disease hospital, National key clinical specialty of Hematology, Department of Hematology, The First People’s Hospital of Yunnan Province, 157 Jinbi Road, Kunming 650032, China.

通讯作者：

通讯机构： [1]Department of Hematology, The First People’s Hospital of Yunnan Province, Kunming, China [2]Yunnan Blood Disease Clinical Medical Center, Kunming, China [3]Yunnan Blood Disease Hospital, Kunming, China d Kunming University of Science and Technology, Kunming, China [*1]Yunnan blood disease clinical medical center, Yunnan blood disease hospital, National key clinical specialty of Hematology, Department of Hematology, The First People’s Hospital of Yunnan Province, 157 Jinbi Road, Kunming 650032, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：